Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study

References

• Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013;15(4):486–493.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GYH, de Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948–954.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb/Pfizer EEIG. Fachinformation. ELIQUIS® 5 mg Filmtabletten. Bristol-Myers Squibb/Pfizer EEIG, 2012. Middlesex/UK; 2012.
   Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Basic E, Hohmann C, et al. Effectiveness and safety of non-vitamin K oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. Thromb Haemost. 2018 Mar;118(3):526-538.
   Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:6.
   Web of Science ®Google Scholar
• Nabauer M, Gerth A, Limbourg T, et al. The registry of the german competence NETwork on atrial fibrillation: patient characteristics and initial management. Europace. 2009;11(4):423–434.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb/Pfizer EEIG. Dossier zur Nutzenbewertung gemäß § 35a SGB V - Apixaban (ELIQUIS ® Filmtabletten): Zur Prophylaxe von Schlaganfällen und systemischen Embolien bei erwachsenen Patienten mit nicht - valvulärem Vorhofflimmern (NVAF) und einem oder mehreren Risikofaktoren. Patienten, die für eine Therapie mit Vitamin - K - Antagonisten geeignet sind. Stand: 14 .12 .2012 Zweckmäßige Vergleichstherapie, Anzahl der Patienten mit therapeutisch bedeutsamem Zusatznutzen, Kosten der Therapie für die GKV, Anforderungen an eine qualitätsgesicherte Anwendung. 2014.
   Google Scholar
• 2017, IQVIA Commercial GmbH & Co. OHG. Frankfurt am Main. All rights reserved. – IQVIA Development of the German pharmaceutical market Q1/2017.; 2017. https://www.iqvia.com/-/media/iqvia/pdfs/cese/germany/publikationen/marktbericht/pharma-marktbericht-erstesquartal2017-iqvia.pdf?la=de-de&hash=F250107A8DB91EC476225567AADA4E1E446374F2 (Accessed 22.01.2017).
   Google Scholar
• Bristol-Myers Squibb/Pfizer EEIG. Forecast model apixaban. . Munich/Berlin,2016.
   Google Scholar
• Statistisches Bundesamt. Bevölkerung Deutschlands bis 2060 – 13. koordinierte Bevölkerungsvorausberechnung. Wiesbaden, Germany; 2015.
   Google Scholar
• Dorian P, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J. 2014;35(28):1897–1906.
   PubMed Web of Science ®Google Scholar
• Statistisches Bundesamt. Ergebnisse aus der laufenden Berechnung von Periodensterbetafeln für Deutschland und die Bundesländer. Wiesbaden, Germany; 2016.
   Google Scholar
• Prochaska JH, Göbel S, Keller K, et al. Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service–results from the prospective, multi-center, observational cohort study thrombEVAL. BMC Med. 2015;13:14.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029–2037.
   PubMed Web of Science ®Google Scholar
• Friberg L, Hammar N, Pettersson H, et al. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J. 2007;28(19):2346–2353.
   PubMed Web of Science ®Google Scholar
• Wilke T, Groth A, Mueller S, et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost. 2012;107(6):1053–1065.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events–European registry in atrial fibrillation (PREFER in AF). Europace. 2014;16(1):6–14.
   PubMed Web of Science ®Google Scholar
• Pisters R, Nieuwlaat R, Lane DA, et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost. 2013;109(2):328–336.
   PubMed Web of Science ®Google Scholar
• Nimptsch U, Mansky T. Trends in acute inpatient stroke care in Germany–an observational study using administrative hospital data from 2005-2010. Dtsch Arztebl Int. 2012;109(51-52:885–892.
   Web of Science ®Google Scholar
• Lancaster TR. The impact of long-term Warfarin therapy on quality of life. Arch Intern Med. 1991;151(10):1944.
   PubMedGoogle Scholar
• Fang MC, Go AS, Chang Y, et al. Death and disability from Warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120(8):700–705.
   PubMed Web of Science ®Google Scholar
• Freedman B, Camm J, Calkins H, et al. Screening for atrial fibrillation: a report of the AF-SCREEN International Collaboration. Circulation. 2017;135(19):1851–1867.
   PubMed Web of Science ®Google Scholar
• Human Mortality Database. UK life tables, 2009. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). Data downloaded May 2011 from www.mortality.org. 2009.
   Google Scholar
• Kirchhof P, Nabauer M, Gerth A, et al. Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost. 2011;105(6):1010–1023.
   PubMed Web of Science ®Google Scholar
• Meinertz T, Kirch W, Rosin L, et al. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol. 2011;100(10):897–905.
   PubMed Web of Science ®Google Scholar
• Bonnemeier H, Bosch RF, Kohlhaussen A, et al. Presentation of atrial fibrillation and its management by cardiologists in the ambulatory and hospital setting: MOVE cross-sectional study. Curr Med Res Opin. 2011;27(5):995–1003.
   PubMed Web of Science ®Google Scholar
• McBride D, Brüggenjürgen B, Roll S, et al. Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice. J Thromb Thrombolysis. 2007;24(1):65–72.
   PubMed Web of Science ®Google Scholar
• Tran-Duy A, Boonen A, van de Laar MAFJ, et al. Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study. Cost Eff Resour Alloc. 2015;13:18.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal. 2010;31(19):2369–2429.
   PubMed Web of Science ®Google Scholar